Business · 26/02/2003Updated: 10/17/2026 · 1 min read
FDA Announces Opportunity for Hearing on Proposal to Revoke Delmont Laboratories' Biologics License
Summary
The FDA is seeking public input on a proposal to revoke Delmont Laboratories' biologics license for Polyvalent Bacterial Antigens due to concerns over the product's potency and potential safety risks.